Suppr超能文献

新型含1,2,3-三唑的双修饰秋水仙碱衍生物:设计、合成及生物活性评价

Novel Double-Modified Colchicine Derivatives Bearing 1,2,3-Triazole: Design, Synthesis, and Biological Activity Evaluation.

作者信息

Krzywik Julia, Nasulewicz-Goldeman Anna, Mozga Witold, Wietrzyk Joanna, Huczyński Adam

机构信息

Department of Medical Chemistry, Faculty of Chemistry, Adam Mickiewicz University, Uniwersytetu Poznańskiego 8, 61-614 Poznań, Poland.

TriMen Chemicals, Piłsudskiego 141, 92-318 Łódź, Poland.

出版信息

ACS Omega. 2021 Sep 28;6(40):26583-26600. doi: 10.1021/acsomega.1c03948. eCollection 2021 Oct 12.

Abstract

A series of 1,4-disubstituted 1,2,3-triazoles having 10-demethoxy-10--methylaminocolchicine core were designed and synthesized the Cu(I)-catalyzed "click" reaction and screened for their cytotoxicity against four cancer cell lines (A549, MCF-7, LoVo, LoVo/DX) and one noncancerous cell line (BALB/3T3). Indexes of resistance (RI) and selectivity (SI) were also determined to assess the potential of the analogues to break drug resistance of the LoVo/DX cells and to verify their selectivity toward killing cancer cells over normal cells. The compounds with an ester or amide moiety in the fourth position of 1,2,3-triazole of 10--methylaminocolchicine turned out to have the greatest therapeutic potential (low IC values and favorable SI values), much better than that of unmodified colchicine or doxorubicin and cisplatin. Thus, they make a valuable clue for the further search for a drug having a colchicine scaffold.

摘要

设计并合成了一系列具有10-去甲氧基-10-甲基氨基秋水仙碱核心的1,4-二取代1,2,3-三唑,通过铜(I)催化的“点击”反应合成,并筛选了它们对四种癌细胞系(A549、MCF-7、LoVo、LoVo/DX)和一种非癌细胞系(BALB/3T3)的细胞毒性。还测定了耐药指数(RI)和选择性指数(SI),以评估类似物突破LoVo/DX细胞耐药性的潜力,并验证它们对癌细胞与正常细胞的杀伤选择性。结果表明,在10-甲基氨基秋水仙碱的1,2,3-三唑第四位带有酯或酰胺部分的化合物具有最大的治疗潜力(低IC值和良好的SI值),远优于未修饰的秋水仙碱、阿霉素和顺铂。因此,它们为进一步寻找具有秋水仙碱骨架的药物提供了有价值的线索。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b37/8515607/df73f240eccc/ao1c03948_0002.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验